News & Press - BioFlorida, Inc.

News & Press

Read about recent events, essential information and the latest community news.

Scientific Advancements
Tuesday, March 8, 2022 (0 Comments - view/add) VySpine Announces FDA Clearance for LumiVy Lumbar IBF System » VySpine Announces FDA Clearance for LumiVy Lumbar IBF System...
Thursday, March 3, 2022 (0 Comments - view/add) Oragenics Announces Positive Data on Their Intranasal SARS-CoV-2 Vaccine Candidate in a Posted Prep » Oragenics Announces Positive Data on Their Intranasal SARS-CoV-2 Vaccine Candidate in a Posted Preprint Manuscript...
Wednesday, February 23, 2022 (0 Comments - view/add) Jupiter Neurosciences, Inc. Announces Completion of Phase I Safety Trial with Enhanced Resveratrol P » Jupiter Neurosciences, Inc. Announces Completion of Phase I Safety Trial with Enhanced Resveratrol Product, JOTROL™...
Tuesday, February 8, 2022 (0 Comments - view/add) AGTC Announces Robust Improvements in Visual Sensitivity in Adult and Pediatric Patients, and Plans » AGTC Announces Robust Improvements in Visual Sensitivity in Adult and Pediatric Patients, and Plans to Continue Clinic...
Thursday, February 3, 2022 (0 Comments - view/add) Biom Pharmaceuticals’ Antiviral Compound Bi121 Shows Broad-spectrum Activity Against Three Variants » Biom Pharmaceuticals’ Antiviral Compound Bi121 Shows Broad-spectrum Activity Against Three Variants of SARS-CoV-2...
Monday, January 31, 2022 (0 Comments - view/add) Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine » Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine - NVX-CoV2373 demonstrated o...
Friday, January 28, 2022 (0 Comments - view/add) Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrate » Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against...
Monday, January 24, 2022 (0 Comments - view/add) Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 » Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in...
Monday, January 24, 2022 (0 Comments - view/add) AIM ImmunoTech Announces Publication of Positive Results from Phase 1/2 Study of Intraperitoneal Che » AIM ImmunoTech Announces Publication of Positive Results from Phase 1/2 Study of Intraperitoneal Chemo-Immunotherapy i...
Thursday, January 20, 2022 (0 Comments - view/add) HCW Biologics Inc. Announces its Lead Product Candidate Shown to Augment Anti-Tumor Activity and Red » HCW Biologics Inc. Announces its Lead Product Candidate Shown to Augment Anti-Tumor Activity and Reduce Side Effects o...
Wednesday, January 5, 2022 (0 Comments - view/add) Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheim » Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer’s Disease...
Monday, January 3, 2022 (0 Comments - view/add) Stuart Therapeutics, Inc. Announces Successful Phase 2 Clinical Trial Results of its Novel Dry Eye C » Stuart Therapeutics, Inc. Announces Successful Phase 2 Clinical Trial Results of its Novel Dry Eye Candidate ST-100 - A...
Thursday, December 23, 2021 (0 Comments - view/add) Merck and Ridgeback’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment o » Merck and Ridgeback’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults W...
Wednesday, December 22, 2021 (0 Comments - view/add) Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment » Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment...
Friday, December 17, 2021 (0 Comments - view/add) ILiAD Biotechnologies Announces First School-Age Participants Enrolled in BPZE1 Pertussis Vaccine Ph » ILiAD Biotechnologies Announces First School-Age Participants Enrolled in BPZE1 Pertussis Vaccine Phase 2b SUPER Clinical...
Friday, December 17, 2021 (0 Comments - view/add) Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 » Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementi...
Tuesday, December 14, 2021 (0 Comments - view/add) KemPharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokine » KemPharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of “Higher-Dose...
Tuesday, December 14, 2021 (0 Comments - view/add) Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Ora » Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment...
Tuesday, December 14, 2021 (0 Comments - view/add) SAS and PERSOWN drive lifesaving insights to reduce COVID spread, improve global health » SAS and PERSOWN drive lifesaving insights to reduce COVID spread, improve global health The partnership combines PERS...
Monday, December 13, 2021 (0 Comments - view/add) Medtronic says study results show alternative spine procedures could reduce opioid use » Medtronic says study results show alternative spine procedures could reduce opioid use December 13, 2021 By Chris Ne...
Thursday, December 9, 2021 (0 Comments - view/add) uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene D » uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene T...
Tuesday, December 7, 2021 (0 Comments - view/add) Psilera Confirms PSIL-002, A New DMT Derivative, is Well-Tolerated and Non-Hallucinogenic from In Vi » Psilera Confirms PSIL-002, A New DMT Derivative, is Well-Tolerated and Non-Hallucinogenic from In Vivo Behavioral Studies...
Monday, December 6, 2021 (0 Comments - view/add) Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trap » Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol®Cyclo™ for the Treatm...
Monday, December 6, 2021 (0 Comments - view/add) Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Le » Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLH...
Wednesday, December 1, 2021 (0 Comments - view/add) Oragenics Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of it » Oragenics Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine...
Tuesday, November 30, 2021 (0 Comments - view/add) First Wave BioPharma Announces Independent Data Monitoring Committee Provides Positive Interim Safet » First Wave BioPharma Announces Independent Data Monitoring Committee Provides Positive Interim Safety Assessment for P...
Friday, November 26, 2021 (0 Comments - view/add) Amcyte Pharma Announces U.S. Launch of Nasitrol® Nasal Spray » Amcyte Pharma Announces U.S. Launch of Nasitrol® Nasal Spray Published: Nov 16, 2021...
Friday, November 26, 2021 (0 Comments - view/add) Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, a » Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational...
Monday, November 22, 2021 (0 Comments - view/add) Hesperos Validates Utility of Human-on-a-Chip® Approach to Model Rare Autoimmune Disease, Myasthenia » Hesperos Validates Utility of Human-on-a-Chip® Approach to Model Rare Autoimmune Disease, Myasthenia Gravis...
Monday, November 22, 2021 (0 Comments - view/add) DePuy Synthes Launches the UNIUM™ System as a Next Generation Power Tools System for Trauma and Smal » DePuy Synthes Launches the UNIUM™ System as a Next Generation Power Tools System for Trauma and Small Bone Procedures T...
Friday, November 19, 2021 (0 Comments - view/add) BioMarin Receives FDA Approval for VOXZOGO™ (vosoritide) for Injection, Indicated to Increase Linear » BioMarin Receives FDA Approval for VOXZOGO™ (vosoritide) for Injection, Indicated to Increase Linear Growth in Children...
Tuesday, November 16, 2021 (0 Comments - view/add) Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate » Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate Tuesday, November 16, 2021 - 02:00pm...
Tuesday, November 16, 2021 (0 Comments - view/add) Cyclo Therapeutics Submits Investigational New Drug Application to U.S. FDA to Advance Trappsol® Cyc » Cyclo Therapeutics Submits Investigational New Drug Application to U.S. FDA to Advance Trappsol® Cyclo™ in Phase 2 Stu...
Saturday, November 6, 2021 (0 Comments - view/add) Medtronic announces early data for the Intrepid™ transcatheter mitral valve replacement (TMVR) syste » Medtronic announces early data for the Intrepid™ transcatheter mitral valve replacement (TMVR) system using new transfem...
Friday, November 5, 2021 (0 Comments - view/add) Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death » Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim...
View "All News Items" »

Member Sign In

Forgot your password?

Don't have a profile?